Century Therapeutics, Inc.
IPSC
$1.92
-$0.01-0.52%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -100.00% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -100.00% | -- | -- |
| Cost of Revenue | -27.04% | -35.65% | -32.95% | -17.27% | -1.33% |
| Gross Profit | 27.04% | -120.71% | 21.85% | 14.79% | -1.55% |
| SG&A Expenses | -1.01% | -2.88% | -26.56% | -18.16% | -6.03% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -21.18% | -27.60% | -31.59% | -17.48% | -2.43% |
| Operating Income | 21.18% | -134.49% | 22.99% | 15.60% | 0.26% |
| Income Before Tax | -6.17% | -128.27% | 43.90% | -10.21% | -4.35% |
| Income Tax Expenses | -- | -- | -103.83% | -- | -- |
| Earnings from Continuing Operations | -6.17% | -128.27% | 46.85% | -10.24% | -4.27% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.17% | -128.27% | 46.85% | -10.24% | -4.27% |
| EBIT | 21.18% | -134.49% | 22.99% | 15.60% | 0.26% |
| EBITDA | 21.48% | -129.16% | 26.32% | 16.70% | -0.54% |
| EPS Basic | 55.50% | -112.57% | 48.00% | -8.00% | 0.74% |
| Normalized Basic EPS | 67.35% | -113.67% | 21.75% | 13.28% | 0.67% |
| EPS Diluted | 55.26% | -112.57% | 48.50% | -8.11% | 0.03% |
| Normalized Diluted EPS | 67.35% | -113.68% | 21.75% | 13.28% | 0.67% |
| Average Basic Shares Outstanding | 138.62% | 124.92% | 2.19% | 2.08% | 5.05% |
| Average Diluted Shares Outstanding | 138.62% | 124.71% | 2.19% | 2.08% | 5.05% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |